Literature DB >> 16175619

Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment.

Sara Montagnese1, Harriet M Gordon, Clive Jackson, Justine Smith, Patrizia Tognella, Nutan Jethwa, R Michael Sherratt, Marsha Y Morgan.   

Abstract

Smooth pursuit eye movements (SPEM) are the conjugate movements used to track the smooth trajectory of small dots. Jerky or 'saccadic' ocular pursuit has been reported in patients with cirrhosis, but no formal assessment of SPEM has ever been undertaken. The aim of this study was to evaluate SPEM in patients with cirrhosis and varying degrees of hepatic encephalopathy. The patient population comprised 56 individuals (31 men, 25 women) of mean age 51.1 (range, 25-70) years, with biopsy-proven cirrhosis, classified, using clinical, electroencephalographic, and psychometric variables, as either neuropsychiatrically unimpaired or as having minimal or overt hepatic encephalopathy; patients were further categorized in relation to their treatment status. The reference population comprised 28 healthy volunteers (12 men, 16 women) of mean age 47.3 (range, 26-65) years. SPEM was assessed using an electro-oculographic technique. Visual inspection of the SPEM recordings showed clear disruption of smooth pursuit in the patients with minimal hepatic encephalopathy, and more pronounced disruption, if not complete loss, of smooth pursuit in patients with overt hepatic encephalopathy. The differences observed in quantifiable SPEM indices between the healthy volunteers/unimpaired patients and those with overt hepatic encephalopathy were significant (P < .05). In conclusion, SPEM performance is impaired in patients with hepatic encephalopathy in parallel with the degree of neuropsychiatric disturbance: the pathophysiology of these changes is unknown, but retinal, extrapyramidal, and attentional abnormalities are likely to play a role. Treatment status confounds the classification of neuropsychiatric status and should be taken into account when categorizing these patients.

Entities:  

Mesh:

Year:  2005        PMID: 16175619     DOI: 10.1002/hep.20855

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  The Treatment of Patients With Hepatic Encephalopathy: Review of the Latest Data from EASL 2010.

Authors:  Kevin D Mullen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

2.  Using saccades to diagnose covert hepatic encephalopathy.

Authors:  Nicholas Cunniffe; Henry Munby; Shona Chan; Defne Saatci; Eric Edison; R H S Carpenter; Dunecan Massey
Journal:  Metab Brain Dis       Date:  2015-01-15       Impact factor: 3.584

Review 3.  Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement.

Authors:  J S Bajaj; J Cordoba; K D Mullen; P Amodio; D L Shawcross; R F Butterworth; M Y Morgan
Journal:  Aliment Pharmacol Ther       Date:  2011-02-09       Impact factor: 8.171

4.  Saccadic latency in hepatic encephalopathy: a pilot study.

Authors:  Florian Krismer; Jonathan C P Roos; Melanie Schranz; Ivo W Graziadei; Sergei Mechtcheriakov; Wolfgang Vogel; R H S Carpenter; Heinz Zoller
Journal:  Metab Brain Dis       Date:  2010-09-18       Impact factor: 3.584

5.  Covert hepatic encephalopathy: does the mini-mental state examination help?

Authors:  Michela Corrias; Matteo Turco; Michele D Rui; Angelo Gatta; Paolo Angeli; Carlo Merkel; Piero Amodio; Sami Schiff; Sara Montagnese
Journal:  J Clin Exp Hepatol       Date:  2014-01-24

Review 6.  Therapeutic studies in hepatic encephalopathy.

Authors:  Kevin D Mullen; Piero Amodio; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2007-12       Impact factor: 3.584

7.  Minimal hepatic encephalopathy is associated to alterations in eye movements.

Authors:  Franc Casanova-Ferrer; Cecilia E García-Cena; Juan-Jose Gallego; Alessandra Fiorillo; Amparo Urios; Alberto Calvo-Córdoba; Maria-Pilar Ballester; María Pilar Ríos; Lucía Durbán; Marta R Hidalgo; Francisco García; Vicente Felipo; Carmina Montoliu
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

8.  Movement Disorders in Non-Wilsonian Hepatic Cirrhotic Patients: The Subgroup Analysis of Various Phenotypes and Associated Risk Factors.

Authors:  Kulthida Methawasin; Piyanant Chonmaitree; Chatchawan Wongjitrat; Suthee Rattanamongkolgul; Thanin Asawavichienjinda
Journal:  J Mov Disord       Date:  2016-03-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.